AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Genes & Diseases Article
PDF (922.8 KB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review Article | Open Access

De novo nucleotide biosynthetic pathway and cancer

Jie Chena,b,1, Siqi Yanga,1, Yingge Lia,b, Xu Ziwenb, Pingfeng Zhanga, Qibin Songa, Yi Yaoa( ), Huadong Peib( )
Cancer Center, Renmin Hospital of Wuhan University, Wuhan, Hubei 430062, China
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C. 20057, USA

Peer review under responsibility of Chongqing Medical University.

1 These authors contributed equally.

Show Author Information

Abstract

De novo nucleotide biosynthetic pathway is a highly conserved and essential biochemical pathway in almost all organisms. Both purine nucleotides and pyrimidine nucleotides are necessary for cell metabolism and proliferation. Thus, the dysregulation of the de novo nucleotide biosynthetic pathway contributes to the development of many human diseases, such as cancer. It has been shown that many enzymes in this pathway are overactivated in different cancers. In this review, we summarize and update the current knowledge on the de novo nucleotide biosynthetic pathway, regulatory mechanisms, its role in tumorigenesis, and potential targeting opportunities.

Keywords

Biosynthetic pathwayCancerde novo synthesisMetabolismNucleotide

References

1

Thierry D, Timothy LB, Yuen YH, et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood. 2002;100(4):1240–1247.
Crossref Google Scholar
2

Siddiqui A, Ceppi P. A non-proliferative role of pyrimidine metabolism in cancer. Mol Metabol. 2020;35(7):100962.
Crossref Google Scholar
3

Vincenzetti S, Polzonetti V, Micozzi D, Pucciarelli S. Enzymology of pyrimidine metabolism and neurodegeneration. Curr Med Chem. 2016;23(14):1408–1431.
Crossref Google Scholar
4

Pareek V, Tian H, Winograd N, Benkovic SJ. Metabolomics and mass spectrometry imaging reveal channeled de novo purine synthesis in cells. Science. 2020;368(29):283–287.
Crossref Google Scholar
5

Zhu J, Thompson CB. Metabolic regulation of cell growth and proliferation. Nat Rev Mol Cell Biol. 2019;20(7):436–450.
Crossref Google Scholar
6

Yin J, Ren W, Huang X, Deng J, Li T, Yin Y. Potential mechanisms connecting purine metabolism and cancer therapy. Front Immunol. 2018;9(30):1697.
Crossref Google Scholar
7

Villa E, Ali ES, Sahu U, Ben-Sahra I. Cancer cells tune the signaling pathways to empower de Novo synthesis of nucleotides. Cancers (Basel). 2019;11(5):688.
Crossref Google Scholar
8

Allsop J, Watts R. Purine de novo synthesis and salvage during testicular development in the rat. Pediatr Res. 1985;19(3):744.
Crossref Google Scholar
9

Robinson AD, Eich ML, Varambally S. Dysregulation of de novo nucleotide biosynthetic pathway enzymes in cancer and targeting opportunities. Cancer Lett. 2020;470(3):134–140.
Crossref Google Scholar
10

Lane AN, Fan TW. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. 2015;43(4):2466–2485.
Crossref Google Scholar
11

Simmer JP, Kelly RE, Rinker A, et al. Mammalian carbamyl phosphate synthetase (CPS). DNA sequence and evolution of the CPS domain of the Syrian hamster multifunctional protein CAD. J Biol Chem. 1990;265(18):10395–10402.
Crossref Google Scholar
12

Li G, Li D, Wang T, He S. Pyrimidine biosynthetic enzyme CAD: its function, regulation, and diagnostic potential. Int J Mol Sci. 2021;22(19):10253.
Crossref Google Scholar
13

Bajzikova M, Kovarova J, Coelho AR, et al. Reactivation of dihydroorotate dehydrogenase-driven pyrimidine biosynthesis restores tumor growth of respiration-deficient cancer cells. Cell Metabol. 2019;29(2):399–416.
Crossref Google Scholar
14

Loffler M, Fairbanks LD, Zameitat E, Marinaki AM, Simmonds HA. Pyrimidine pathways in health and disease. Trends Mol Med. 2005;11(5):430–437.
Crossref Google Scholar
15

Aaron MH, Vivian CH, Laura VD, et al. Amino acids rather than glucose account for the majority of cell mass in proliferating mammalian cells. Dev Cell. 2016;36(5):540–549.
Crossref Google Scholar
16

Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17(4):351–359.
Crossref Google Scholar
17

Zhao XA, Petrashen AP, Sanders JA, Peterson AL, Sedivy JM. SLC1A5 glutamine transporter is a target of MYC and mediates reduced mTORC1 signaling and increased fatty acid oxidation in long-lived Myc hypomorphic mice. Aging Cell. 2019;18(3):e12947.
Crossref Google Scholar
18

Gao P, Irina T, Chang TC, et al. c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism. Cancer Res. 2009;458(7239):762–765.
Crossref Google Scholar
19

Alex JB, Peng IC, Fan YJ, et al. Oncogenic myc induces expression of glutamine synthetase through promoter demethylation. Cell Metabol. 2015;22(6):1068–1077.
Crossref Google Scholar
20

Bernfeld E, Foster DA. Glutamine as an essential amino acid for KRas-driven cancer cells. Trends Endocrin Met. 2019;30(16):357–368.
Crossref Google Scholar
21

Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033.
Crossref Google Scholar
22

Pei YZ, Qian YJ, Wang H, Tan L. Epigenetic regulation of ferroptosis-associated genes and its implication in cancer therapy. Front Oncol. 2022;12(23):112–117.
Crossref Google Scholar
23

Feng J, Li JJ, Wu LW, et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2020;39(1):126.
Crossref Google Scholar
24

Robey RB, Hay N. Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene. 2006;25(7):4683–4696.
Crossref Google Scholar
25

Wiernan HL, Wofford JA, Rathmell JC. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell. 2007;18(4):1437–1446.
Crossref Google Scholar
26

Saha A, Connelly S, Jiang JJ, et al. Akt phosphorylation and regulation of transketolase is a nodal point for amino acid control of purine synthesis. Mol Cell. 2014;55(2):264–276.
Crossref Google Scholar
27

Luciano-Mateo F, Hernandez-Aguilera A, Cabre N, et al. Nutrients in energy and one-carbon metabolism: learning from metformin users. Nutrients. 2017;9(2):121.
Crossref Google Scholar
28

Andrea R, Alessandra N, Francesca R, Antonella T, Marina B, Delia M. One-carbon metabolism: biological players in epithelial ovarian cancer. Int J Mol Sci. 2018;19(7):2092.
Crossref Google Scholar
29

Nilsson R, Jain M, Madhusudhan N, et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun. 2014;5(17):3128.
Crossref Google Scholar
30

Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;169(2):361–371.
Crossref Google Scholar
31

Issam BS, Gerta H, Stephane JHR, John MA, Brendan DM. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science. 2016;351(6274):728–733.
Crossref Google Scholar
32

Hsieh AL, Walton ZE, Altman BJ, Stine ZE, Dang CV. MYC and metabolism on the path to cancer. Semin Cell Dev Biol. 2015;43(18):11–21.
Crossref Google Scholar
33

Mannava S, Grachtchouk V, Wheeler LJ, et al. Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle. 2008;7(15):2392–2400.
Crossref Google Scholar
34

Cunningham JT, Moreno MV, Lodi A, Ronen SM, Ruggero D. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell. 2014;157(18):1088–1103.
Crossref Google Scholar
35

Boyd KE, Farnham PJ. Myc versus USF: discrimination at the cad gene is determined by core promoter elements. Mol Cell Biol. 1997;17(5):2529–2537.
Crossref Google Scholar
36

Carvajal LA, Hamard PJ, Tonnessen C, Manfredi JJ. E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression. Gene Dev. 2012;26(14):1533–1545.
Crossref Google Scholar
37

Jiang P, Du WJ, Wu MA. Regulation of the pentose phosphate pathway in cancer. Protein Cell. 2014;5(18):592–602.
Crossref Google Scholar
38

Li S, Lu Y, Peng B, Ding J. Crystal structure of human phosphoribosylpyrophosphate synthetase 1 reveals a novel allosteric site. Biochem J. 2007;401(1):39–47.
Crossref Google Scholar
39

Qian X, Li X, Tan L, et al. Conversion of PRPS hexamer to monomer by AMPK-mediated phosphorylation inhibits nucleotide synthesis in response to energy stress. Cancer Discov. 2018;8(1):94–107.
Crossref Google Scholar
40

Jing X, Wang XJ, Zhang T, et al. Cell-cycle-dependent phosphorylation of PRPS1 fuels nucleotide synthesis and promotes tumorigenesis. Cancer Res. 2019;79(28):4650–4664.
Crossref Google Scholar
41

Li X, Qian X, Peng LX, et al. A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation. Nat Cell Biol. 2016;18(5):561–571.
Crossref Google Scholar
42

Li XJ, Qian X, Lu ZM. Fructokinase A acts as a protein kinase to promote nucleotide synthesis. Cell Cycle. 2016;15(20):2689–2690.
Crossref Google Scholar
43

Aoki T, Weber G. Carbamoyl phosphate synthetase (Glutamine-Hydrolyzing) - increased activity in cancer-cells. Science. 1981;212(13):463–465.
Crossref Google Scholar
44

Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–484.
Crossref Google Scholar
45

Issam BS, Jessica JH, John MA, Brendan DM. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science. 2013;339(6125):1323–1328.
Crossref Google Scholar
46

Sigoillot FD, Kotsis DH, Serre V, Sigoillot SM, Evans DR, Guy HI. Nuclear localization and mitogen-activated protein kinase phosphorylation of the multifunctional protein CAD. J Biol Chem. 2005;280(10):25611–25620.
Crossref Google Scholar
47

Sigoillot FD, Berkowski JA, Sigoillot SM, Kotsis DH, Guy HI. Cell cycle-dependent regulation of pyrimidine biosynthesis. J Biol Chem. 2003;278(34):3403–3409.
Crossref Google Scholar
48

Sigoillot FD, Kotsis DH, Masko EM, Bame M, Evans DR, Evans HI. Protein kinase C modulates the up-regulation of the pyrimidine biosynthetic complex, CAD, by MAP kinase. Front Biosci. 2007;12(4):3892–3898.
Crossref Google Scholar
49

Katherine MA, Zhang G, Li H, et al. Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. Cell Rep. 2013;3(25):1252–1265.
Crossref Google Scholar
50

Chon J, Stover PJ, Field MS. Targeting nuclear thymidylate biosynthesis. Mol Aspect Med. 2017;53(16):48–56.
Crossref Google Scholar
51

Moloy TG, Chen GA, Balabhadrapatruni VSKC, et al. Role and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer. Oncotarget. 2015;6(27):23445–23461.
Crossref Google Scholar
52

Ridder D, Schindeldecker M, Berndt K, et al. Key enzymes in pyrimidine synthesis, CAD and CPS1, predict prognosis in hepatocellular carcinoma. Cancers. 2021;59(1):1722–1727.
Crossref Google Scholar
53

Chen JN, Yu Y, Li H, et al. Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer. Mol Cancer. 2019;18(33):1–16.
Crossref Google Scholar
54

Qiu ZP, Guo WJ, Wang QF, et al. MicroRNA-124 reduces the pentose phosphate pathway and proliferation by targeting PRPS1 and RPIA mRNAs in human colorectal cancer cells. Gastroenterol. 2015;14(10):1587–1598.
Crossref Google Scholar
55

Zhang X, Li F, Zhou Y, et al. Long non-coding RNA AFAP1-AS1 promotes tumor progression and invasion by regulating the miR-2110/Sp1 axis in triple negative breast cancer. Oncol. 2020;11(10):101–132.
Crossref Google Scholar
56

Li B, Li H, Bai Y, et al. Negative feedback-defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL. Nat Med. 2015;21(6):563–571.
Crossref Google Scholar
57

Joseph TM, Armand B, Christine RC, Hollis DS, Nouri N. Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. Pharmacol Ther. 2019;195(6):111–131.
Crossref Google Scholar
58

Wang X, Yang K, Wu Q, et al. Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells. Sci Transl Med. 2019;11(504):4972.
Crossref Google Scholar
59

Patricia C, Zhang L, Michael U, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172.
Crossref Google Scholar
60

Brown KK, Spinelli JB, Asara JM, Toker A. Adaptive reprogramming of de novo pyrimidine synthesis is a metabolic vulnerability in triple-negative breast cancer. Cancer Discov. 2017;7(4):391–399.
Crossref Google Scholar
61

He YC, Cao J. Chen JW, Pan DY; Zhou YK. Influence of methionine/valine-depleted enteral nutrition on nucleic acid and protein metabolism in tumor-bearing rats. World J Gastroenterol. 2003;9(4):145–148.
Crossref Google Scholar
62

Vultaggio-Poma V, Sarti AC, Di Virgilio F. Extracellular ATP: a feasible target for cancer therapy. Cells. 2020;9(11):2496.
Crossref Google Scholar
63

Naffouje R, Grover P, Yu H, et al. Anti-tumor potential of IMP dehydrogenase inhibitors: a century-long story. Cancers (Basel). 2019;11(9):1346.
Crossref Google Scholar
64

Koch J, Mayr JA, Alhaddad B, et al. CAD mutations and uridine-responsive epileptic encephalopathy. Brain. 2017;140(2):279–286.
Crossref Google Scholar
Genes & Diseases
Volume 10 Issue 6,
November 2023
Pages 2331-2338
DOI: 10.1016/j.gendis.2022.04.018
Cite this article:
Chen J, Yang S, Li Y, et al. De novo nucleotide biosynthetic pathway and cancer. Genes & Diseases, 2023, 10(6): 2331-2338. https://doi.org/10.1016/j.gendis.2022.04.018

376

Views

2

Downloads

14

Crossref

14

Web of Science

12

Scopus

0

CSCD

Altmetrics
Received: 25 March 2022
Accepted: 18 April 2022
Published: 16 May 2022
© 2022 The Authors.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return